“Navigating Routes to Commercial Success in Cell and Gene Therapy,” authored by Franjo Hanzl, VP, Business Development, Commercial, EVERSANA, Dr. Lisa Johnson-Pratt, Strategic, Commercial Advisor, Ananias Ventures and Siddharth Agrawal, Senior Principal, Commercial Strategy, EVERSANA, discusses the unique challenges faced by companies developing and commercializing cell and gene therapies (CGTs). The paper highlights the significant potential of CGTs in treating previously incurable diseases and the need for a tailored approach to commercialization given the complexity of these therapies, high development costs, and regulatory hurdles. It provides an overview of the current market landscape and emerging trends in CGT development and commercialization, including the importance of real-world evidence, patient engagement, and pricing and reimbursement strategies. The paper also outlines best practices for successfully navigating the commercialization journey, including the importance of a cross-functional approach, strong data management capabilities, and proactive engagement with payers and other stakeholders.
The paper emphasizes that effective commercialization of CGTs requires a deep understanding of the unique characteristics of these therapies and a strategic approach that balances patient needs, clinical outcomes, and financial sustainability. It suggests that companies can improve their chances of success by investing in robust data and analytics capabilities, building partnerships with key stakeholders, and adopting a flexible and iterative approach to product development and commercialization. The paper concludes by highlighting the importance of collaboration between industry, regulators, and payers to overcome the challenges of commercializing CGTs and ensure that patients can access these life-changing therapies.
Complete the form below to download the full paper.
Author
As a leader of the commercial team in Europe, Franjo helps clients solve complex industry challenges while supporting streamlined commercialisation strategies that get innovative therapies to patients across borders. He joined EVERSANA with more…
Sid brings 20 years of experience in pharma sales, marketing and management consulting. He partners with pharmaceutical industry clients at various levels and functions (brand team, medical affairs, clinical development, regulatory, product development) to…